Tina Morwick, Angela Berry, Janice Brickwood, Mario Cardozo, Katrina Catron, Molly DeTuri, Jonathan Emeigh, Carol Homon, Matt Hrapchak, Stephen Jacober, Scott Jakes, Paul Kaplita, Terence A Kelly, John Ksiazek, Michel Liuzzi, Ronald Magolda, Can Mao, Daniel Marshall, Daniel McNeil, Anthony Prokopowicz, Christopher Sarko, Erika Scouten, Cynthia Sledziona, Sanxing Sun, Jane Watrous, Jiang Ping Wu, Charles L Cywin
High-throughput screening is routinely employed as a method for the identification of novel hit structures. Large numbers of active compounds are typically procured in this way and must undergo a rigorous validation process. This process is described in detail for a collection of screening hits identified as inhibitors of IkappaB kinase-beta (IKKbeta), a key regulatory enzyme in the nuclear factor-kappaB (NF-kappaB) pathway. From these studies, a promising hit series was selected. Subsequent lead generation activities included the development of a pharmacophore hypothesis and structure-activity relationship (SAR) for the hit series...
May 18, 2006: Journal of Medicinal Chemistry